Applied Clinical Trials: "Antidote Incorporates Patient Centricity in Subject Enrollment"
Applied Clinical Trials recently interviewed our Chief Development Officer, Tom Krohn, on the work we're doing to keep patients at the center of clinical trials.
"A few years ago, the FDA announced the launch of patient centric initiatives, which led to the initiation of The Patient Preference Initiative and the Patient Engagement Advisory Committee, all geared towards incorporating the patient’s voice in medical product development. While subject enrollment has focused mainly on finding the right patients for specific studies, Antidote (formerly TrialReach) has taken a patient centered approach towards clinical trial matching by focusing on the patient. Tom Krohn, former Director of Clinical Open Innovation at Eli Lilly, and current Chief Development Officer at Antidote, will discuss the approach in this interview."